Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$11.65 USD
+0.33 (2.92%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $11.66 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PHAT 11.65 +0.33(2.92%)
Will PHAT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PHAT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHAT
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates
Zacks.com featured highlights include Phathom Pharmaceuticals, Universal Stainless & Alloy Products and Arlo Technologies
PHAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Top Breakout Stocks Worth a Buy for Attractive Returns
Does Phathom Pharmaceuticals, Inc. (PHAT) Have the Potential to Rally 81.38% as Wall Street Analysts Expect?
Phathom Pharmaceuticals, Inc. (PHAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Other News for PHAT
Optimistic Outlook on Phathom Pharmaceuticals Despite Temporary Prescription Dip
Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
Wall Street Breakfast: The Week Ahead
Optimistic Outlook for V oquezna’s Market Penetration and Future Sales Despite Temporary Dip
Catalyst Watch: Nike earnings, Datadog event, Norfolk Southern decision, and an oil field-crypto IPO